Table 2.

Summary of the diseases status of the 11 patients in the adaptive therapy trial

Subject ID	Gleason	Site of metastasis	Pre-abiraterone PSA	Abiraterone dose %
1001	8(4 + 4)	Bone, soft tissue	6.06	62%
1002	8(4 + 4)	Bone	58.57	55%
1003	9 (5 + 4)	Bone, lymph node	68	42%
1005	7(4 + 3)	Lymph node	95.86	87%
1006	8(4 + 4)	Bone	15.25	23%
1007	6(3 + 3)	Bone	109.4	21%
1009	6(3 + 3)	Bone	13.55	53%
1010	7(3 + 4)	Bone	17.33	45%
1011	9(4 + 5)	Lymph node	2.42	53%
1012	8(4 + 4)	Bone	4.17	21%
1014	7(4 + 3)	Bone	11.83	52%
Average cumulative abiraterone				47%

The cumulative abiraterone dose as a percentage of SOC dose is shown for each patient in the trial